No Effect of IDU on Postoperative Mortality in Infective Endocarditis
Early postoperative mortality may not differ between infective endocarditis caused by IDU and non- IDU causes.
Endocarditis
Restrictive OPAT Criteria for Infective Endocarditis May Need Revision
A less restrictive criteria for the use of OPAT for patients with infective endocarditis than current IDSA guidelines was efficacious and safe.
Adjunctive Cefiderocol Treats XDR P aeruginosa Endocarditis
Cefiderocol, a novel siderophore cephalosporin, may be successful in patients with persistently bacteremic nosocomial native aortic valve endocarditis.
Infective Endocarditis Incidence Increased After 2007 AHA Recommendations
The 2007 AHA recommendation for antibiotic prophylaxis for only patients at high risk for infective endocarditis may result in increased incidence of the infection.
Drug Use-Associated Infective Endocarditis: An Emerging Public Health Issue
There has been a marked increase in the rates of overall hospitalizations and hospital stays that include surgery for drug use-associated infective endocarditis.
Risk Assessment Reduces Length of Hospital Stay, Costs in Patients who Inject Drugs
A 9-point risk assessment (IVAT) identified persons with a history of injection drug use (IDU) safe for discharge and reduced the mean length of hospital stay (ALOS) by 20 days and total direct cost by 33%.
New Q Fever Foci Identified, Including Acute Endocarditis, Lymphadenitis
Acute endocarditis, lymphadenitis, and bone marrow involvement in hemophagocytic syndrome have been newly identified as Q fever foci.
Partial Oral Antibiotics Noninferior to Continuous IV in Left-Sided Endocarditis
Changing to oral antibiotics was non-inferior to continued intravenous antibiotic treatment
Factors Increasing Risk for Hemorrhagic Stroke After Infective Endocarditis
The apparent increase in risk for hemorrhagic stroke among patients with previous infective endocarditis was explained by the mediating factors of mechanical heart valve insertion, atrial fibrillation, and anticoagulation medication.
How Many Chances Are Too Many? Treating Recurrent Infective Endocarditis in IV Drug Users
How many second chances should a drug user get? As many as it takes for us — physicians, society, government, and the healthcare system — to get it right.
Next post in Features
